克雷布斯循环衍生物,二甲基 fumarate 和 itaconate,控制在炎症性人类微质细胞系中的代谢重编程
Moris Sangineto1, Martina Ciarnelli1, Archana Moola1
1Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Mitochondrion
|September 14, 2024
概括
甲基-2-酸盐 (DMF) 和伊塔康酸盐 (ITA) 通过调节克雷布斯循环中间体,恢复激活的微质中的正常新陈代谢. 虽然这两种化合物都表现出抗炎作用,但伊塔康酸盐通过抑制线粒体复合物I和II活动,更有效地抵消氧化应激.
科学领域:
- 神经免疫学 神经免疫学
- 细胞的新陈代谢
- 线粒体生物学 线粒体生物学
背景情况:
- 代谢重编程是巨细胞 (包括微质细胞) 炎症反应的核心.
- 克雷布斯循环中间体在这些过程中充当关键信号分子.
- 了解微质代谢是开发神经炎症治疗方法的关键.
研究的目的:
- 研究克雷布斯循环衍生物二甲基-2-酸盐 (DMF) 和伊塔科纳酸盐 (ITA) 对活化的人类微质细胞 (HMC3) 的代谢作用.
- 为了比较DMF和ITA调节线粒体活动和氧化应激的不同机制.
- 评估DMF和ITA作为神经炎症疾病治疗药物的潜力.
主要方法:
- 使用了人类微质克隆3 (HMC3) 细胞系,通过脂多糖 (LPS) 激活.
- 分析了细胞生物能量学,包括糖解和线粒体呼吸.
- 量化了DMF和ITA治疗对线粒体复合体I和II活性和氧化应激标志物的影响.
主要成果:
- 用LPS激活的HMC3细胞表现出高水平的糖解和线粒体呼吸.
- 两种DMF和ITA治疗在很大程度上恢复了正常的新陈代谢概况.
- DMF使线粒体复合体I活动正常化,而ITA则降低了复合体I和II活动.
- 与DMF相比,ITA在抵消氧化应激方面表现出更高的有效性.
结论:
- 尽管具有相似的生物能和抗炎效果,但DMF和ITA在激活的微质中差异调节线粒体的超活性.
- 伊塔科纳酸对线粒体复合体I和II的强烈抑制表明,在神经炎症中减轻氧化应激是一种更有效的策略.
- 这些发现凸显了利用特定的克雷布斯循环衍生物准微质代谢的治疗潜力.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


